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Abstract
Introduction: The induced pluripotent stem cell (iPSC) technology allows generation of patient-specific pluripotent
stem cells, thereby providing a novel cell-therapy platform for severe degenerative diseases. One of the key issues
for clinical-grade iPSC derivation is the accessibility of donor cells used for reprogramming.
Methods: We examined the feasibility of reprogramming mobilized GMP-grade hematopoietic progenitor cells
(HPCs) and peripheral blood mononuclear cells (PBMCs) and tested the pluripotency of derived iPS clones.
Results: Ectopic expression of OCT4, SOX2, KLF4, and c-MYC in HPCs and PBMCs resulted in rapid iPSC derivation.
Long-term time-lapse imaging revealed efficient iPSC growth under serum- and feeder-free conditions with
frequent mitotic events. HPC- and PBMC-derived iPS cells expressed pluripotency-associated markers, including
SSEA-4, TRA-1-60, and NANOG. The global gene-expression profiles demonstrated the induction of endogenous
pluripotent genes, such as LIN28, TERT, DPPA4, and PODXL, in derived iPSCs. iPSC clones from blood and other cell
sources showed similar ultrastructural morphologies and genome-wide gene-expression profiles. On spontaneous
and guided differentiation, HPC- and PBMC-derived iPSCs were differentiated into cells of three germ layers,
including insulin-producing cells through endodermal lineage, verifying the pluripotency of the blood-derived iPSC
clones.
Conclusions: Because the use of blood cells allows minimally invasive tissue procurement under GMP conditions
and rapid cellular reprogramming, mobilized HPCs and unmobilized PBMCs would be ideal somatic cell sources for
clinical-grade iPSC derivation, especially from diabetes patients complicated by slow-healing wounds.
Introduction
Because embryonic stem (ES) cells can self-renew indefi-
nitely and differentiate into any cell present in the adult
organism, ES cells provide a unique platform for regen-
erative medicine approaches. In early 2009, the US Food
and Drug Administration (FDA) approved the first clini-
cal trial using ES cells in patients with spinal cord inju-
ries. Although the FDA temporarily placed the trial on
hold because of concerns over the risk of ES-derived
cyst formation, the clinical hold was lifted, and the first
patient for ES cell treatment was enrolled by Geron in
late 2010 [1]. The use of ES-derived, terminally differen-
tiated retinal pigment epithelium cells for Stargardt
macular dystrophy and dry age-related macular degen-
eration was also approved by the FDA, and Advanced
Cell Technology is currently enrolling patients [2].
Despite these advances in clinical applications, the use
of ES cells is associated with ethical issues and immuno-
logic mismatch, which could affect their widespread use
in the clinic.
The induced pluripotent stem cell (iPSC) technology
allows generation of autologous pluripotent stem cells
without using an embryonic cell source. Expression of
the transcription factors OCT3/4, SOX2, KLF4, and c-
MYC [3-7] or OCT-3/4, SOX2, NANOG, and LIN28 [8]
in somatic cells results in iPSCs, which have phenotypes
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any medium, provided the original work is properly cited.very similar to those of ES cells, including the morphol-
ogy, self-renewal, and pluripotent potentials, and expres-
sion of pluripotency-associated factors, including SSEA-
4 and TRA-1-60. Global gene-expression analysis of
human iPSCs has also revealed patterns similar to those
of human ES cells, with notable upregulation of pluripo-
tency-associated genes such as OCT4, SOX2, NANOG,
TERT, and DPPA4 [3-5,8]. Similar to ES cells, iPSCs can
be differentiated into various cell types, such as insulin-
producing cells [9-11], neurons [12], cardiomyocytes
[13-15], and cells of hematopoietic lineages [13]. Various
types of somatic cells have been successfully repro-
grammed, including fibroblasts, stomach and liver cell
cultures [16], human keratinocytes (HKs) [17,18], frozen
human monocytes [19], cord blood cells [20-22], and
blood cells [23,24], including mature B [25-28] and T
lymphocytes [29-32]. For clinical applications, it would
be ideal if iPSCs could be generated from somatic cells
through a minimally invasive tissue-procurement proce-
dure under GMP-compliant process. In this regard,
blood cells are one of the most promising cell sources
for clinical-grade iPSC derivation.
Here we examined the feasibility of iPSC derivation
from GMP-grade mobilized hematopoietic progenitor
cells (HPCs) and unmobilized peripheral blood mono-
nuclear cells (PBMCs), and characterized derived iPSCs
for global gene-expression profiles and pluripotency.
Materials and methods
All studies were approved by the Institutional Review
Board and Institutional Animal Care and Use Committee.
Cells
GMP-grade HPCs were originally harvested from
patients for stem cell therapy. Specifically, HPCs were
harvested after mobilization by injection with granulo-
cyte colony-stimulating factor for 5 days in the Human
Cellular Therapy Laboratory at the Mayo Clinic. Those
cell products are routinely discarded as clinical wastes
when patients have died before the initiation of stem
cell therapy. We received de-identified clinical-waste
HPCs from the Human Cellular Therapy Laboratory for
iPSC derivation. The use of clinical-waste HPCs for
iPSC generation was approved by the Institutional
Review Board, including the Biospecimens Subcommit-
tee. For mononuclear myeloid cell derivation, 10 ml of
whole blood was purchased and used to isolate PBMCs,
as reported previously [33,34].
Lentiviral vector production
Pluripotency-associated factor-expressing lentiviral vec-
tors, pSIN-OCT4, pSIN-SOX2, pSIN-KLF4, and pSIN-
cMYC were described previously [12]. These vectors
were produced by transient transfection of 293T cells.
Vector titers were determined with immunostaining
[12].
iPSC derivation
HPCs and PBMCs were cultured overnight in StemSpan
H3000 serum-free medium (StemCell Technologies,
Vancouver, Canada), which contains only human-
derived or recombinant human proteins, supplemented
with StemSpan CC100 cytokine cocktail (StemCell
Technologies). Cells (10
5 cells/500 μl of medium in each
well) in uncoated wells of a 24-well plate were then
transduced with four stemness factor-expressing lenti-
viral vectors overnight. One third of the culture super-
natants were carefully removed and replaced daily with
H3000 growth medium supplemented with CC100 cyto-
kine cocktail. Three days after vector infection, cells in a
well of a 24-well plate were transferred to a Matrigel
( B DB i o s c i e n c e s ,B e d f o r d ,M A ) - c o a t e dw e l lo fa6 - w e l l
plate. Starting 5 days after vector infection, cells were
maintained in HEScGRO medium (100 ml; Millipore,
Billerica, MA) supplemented with mTeSR-1 mainte-
nance media (25 ml; StemCell Technologies) [11]. 7 to
10 days after vector infection, the reprogrammed cells
began to form colonies with iPS morphology. At 2 to 3
weeks after vector infection, cultures were treated with
Cell Dissociation Buffer (Invitrogen, Grand Island, NY)
for 5 to 10 minutes to help lift clones, and individual
iPSC-like clones were carefully picked up with a P200
pipette, and placed into Matrigel-coated wells in a 96-
well plate. To prevent spontaneous differentiation, the
iPSC culture medium was replaced daily, and differen-
tiated cells in the cultures were manually removed with
a pipette tip. As the clones grew, cultures were
expanded into larger culture plates for further character-
ization. Clones were preserved by using Xeno-FREEze
Human Embryonic Stem Cell Freezing Medium (Milli-
pore). A verified iPSC clone, HCF1, from primary
human fibroblast (HCF) cells, was described previously
[11]. Primary human keratinocytes and keratinocyte-
derived iPSC clones were also used as controls [35].
Immunostaining and alkaline phosphatase staining
For immunostaining of iPSC, cells were fixed for 20
minutes at room temperature in 4% paraformaldehyde
solution in PBS, washed several times in PBS, and
blocked for 30 minutes in PBS with 5% fetal bovine
serum. Cells were then stained with primary antibodies
overnight at 4°C, rinsed with PBS, and incubated with
secondary antibodies for 1 hour at RT. For immunos-
taining of differentiated cells, cells at different stages of
differentiation were fixed and stained with primary and
secondary antibodies. Primary antibodies used for char-
acterization of iPSC and iPSC-derived cells were SSEA-4
and TRA-1-60 (Millipore, #SCR001), OCT4 (Cell
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(Abcam, #ab21624, Cambridge, MA), mouse anti-
SOX17 (R&D Systems, #MAB1924, Minneapolis, MN),
rabbit anti-HNF3 beta/FOXA2 (Millipore, #07-633), rab-
bit anti-PDX1 (Santa Cruz Biotechnology, #sc-25403,
Santa Cruz, CA) and mouse anti-insulin (Sigma, #I2018,
St. Louis, MO). Texas Red-conjugated donkey-anti-rab-
bit IgG (Jackson ImmunoResearch Laboratories, #711-
075-152, West Grove, PA), Texas Red-conjugated don-
key-anti-mouse IgG (Jackson ImmunoResearch Labora-
tories, #715-075-151), FITC-conjugated donkey-anti-
rabbit IgG (Jackson ImmunoResearch Laboratories,
#711-095-152), and FITC-conjugated donkey-anti-mouse
IgG (Jackson ImmunoResearch Laboratories, #715-095-
151) were used as secondary antibodies. DAPI was used
for counterstaining. Stained cells were analyzed by using
a confocal laser-scanning microscope (Zeiss, LSM 510
confocal scanning laser system).
Spontaneous differentiation
For spontaneous differentiation, iPSC clones were disso-
ciated by using collagenase IV for 30 minutes and plated
on low-adhesion plates in basal HEScGRO medium
without bFGF. Embryoid bodies (EBs) were cultured as
a suspension for 7 to 10 days and adherent in DMEM
with 20% FBS for additional 7 to 10 days. For immuno-
fluorescence analysis, cells were fixed with 4% PFA for
20 minutes at RT. Immunostaining was performed as
described earlier. Primary antibodies against FOXA2 for
endoderm, beta-III tubulin (Abcam, #41489) for ecto-
derm, and CD31 (Santa Cruz Biotechnology, #SC1506)
for mesoderm were used, whereas Texas Red-conjugated
donkey anti-rabbit IgG (Jackson ImmunoResearch
Laboratories, #711-075-152), and FITC-conjugated don-
key anti-chicken IgG (Jackson ImmunoResearch Labora-
tories, #703-095-155) served as secondary antibodies.
In vivo differentiation of derived iPS cells
SCID-beige mice were anesthetized, and the kidney was
externalized for iPS transplantation under the kidney
capsule. A small incision was made in the kidney cap-
sule, and a blunt needle used to create a pocket under
the kidney capsule. After iPSC injection into the pocket,
the kidney was placed back into the abdomen, and the
incision closed with a Vicryl suture. Mice were main-
tained for 4 weeks and killed for harvesting normal and
iPS-transplanted kidneys. OTC-embedded frozen tissues
were cryo-sectioned for H&E staining.
Differentiation of derived iPS cells into insulin-produ-
cing cells iPSCs were differentiated into insulin-produ-
cing cells, as reported previously with minor
modifications [11]. At the first step of differentiation,
human iPSC clones were treated with 25 ng/ml Wnt3a
(R&D Systems) and 100 ng/ml activin A (Peprotech,
Rocky Hill, NJ) in advanced RPMI (Invitrogen) with
Pen/Strep for 1 day, followed by treatment with 100 ng/
ml activin A in advanced RPMI supplemented with 0.2%
fetal calf serum (FBS) (Invitrogen) for 2 days. At step
two, cells were cultured in high-glucose DMEM (Invi-
trogen), supplemented with 20% (vol/vol) advanced
RPMI medium containing 50 ng/ml FGF10 (R&D sys-
tems), 0.25 μmol/L KAAD-cyclopamine (CYC), and 2%
FBS for 2 days. Cells were then treated with 50 ng/ml
FGF10, 0.25 μmol/L CYC, and 2 μmol/L all-trans reti-
noic acid (RA) (Sigma) in high-glucose DMEM (Invitro-
gen) supplemented with 20% advanced RPMI, Pen/
Strep, 1 × B27 supplement (Invitrogen) for 4 days at
step three. Cells were then cultured in the presence of
50 ng/mL FGF10, 300 nmol/L ILV (Axxora, San Diego,
CA), and 55 nmol/L GLP-1 (Sigma) in DMEM (high
glucose) supplemented with 20% advanced RPMI and 1
× B27 for 4 days at step four. In step five, differentiation
medium included 10 μmol/L DAPT (Sigma) and 55
nmol/L GLP-1 in DMEM (high glucose) with 20%
advanced RPMI and 1 × B27, and the culture lasted for
6 days.
Finally, in step six, cells were cultured in the presence
of 50 ng/ml hepatocyte growth factor (HGF) (R&D sys-
tems), 50 ng/ml insulin-like growth factor 1 (IGF-1)
(R&D Systems), and 55 nmol/L GLP-1 in CMRL-1066
medium (Invitrogen) with 1 × B27 for 8 days. All differ-
entiation experiments were performed in triplicate, and
repeated at least twice.
Microarray
Total RNA was isolated by using TRIzol (Invitrogen)
and further purified by using RNeasy Plus spin columns
( Q I A G E N ,V a l e n c i a ,C A ) .T u r b oD N A - f r e eD N a s e
(Ambion, Austin, TX) was used to digest all genomic
DNA that could lead to false-positive gene-expression
results. The RNA quantity and purity was measured
with a Nanodrop spectrophotometer (Thermo Scientific,
Wilmington, DE), and the RNA integrity was deter-
mined by using the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). Microarray analysis was
performed by using the Affymetrix HG-U133 Plus2
GeneChip Array platform (Affymetrix, Santa Clara, CA).
Data were preprocessed by using standard in-house
MicroArray Pre-Processing workflow, and hierarchical
clustering was performed by Pearson Dissimilarity. To
compare the transcriptome of blood-derived iPSCs, the
data set of epidermal keratinocytes (HK, SW3, SW4,
and SW8), two keratinocyte-derived iPSC clones (SW3
b and SW4 N1) and human fibroblast (FB)-derived iPSC
clone HCF1 [11] were used. A t test was performed to
analyze the significance of the changes (P <0 . 0 5 )i nt h e
normalized gene-expression levels between HK and
iPSC clones, or between blood-derived iPSC clones and
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ware (kindly provided by Dr. Euan Ashley, Stanford
School of Medicine) was used to generate the heatmap
for the transcriptome data set. The registered GEO tran-
scriptome database (GSM551202, human ES H9 cells;
GSM452255, freshly isolated PBMC; GSM178554, mobi-
lized HPCs) was used to analyze the similarities between
blood-derived iPSCs and human ES cells or non-repro-
grammed PBMCs and HPCs. Microarray data have been
deposited in the NCBI Gene Expression Omnibus
(GEO) and are accessible through GEO Series accession
number GSE33536 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE33536).
Results and discussion
Cellular reprogramming of HPCs and PBMCs into iPSCs
HPCs and PBMCs were cultured overnight in a serum-
free medium with CC100 cytokine cocktail (recombinant
Flt-3, SCF, IL-3, and IL-6), and transduced with four
stemness factor-expressing lentiviral vectors at a multi-
plicity of infection (MOI) of 5 each. When transduced,
cells were transferred to Matrigel-coated culture plates 3
days after infection, a subset of cells attached to the
plate. At 1 to 2 weeks after vector transduction, small,
reprogrammed colonies, characterized by the morphol-
ogy of sharp-edged, flat, and tightly packed cells, were
observed (Figure 1a). No iPSC-like colony formation
was observed in untransduced cells (Figure 1a). From
t r a n s d u c e dH P C sa n dP B M C s ,w ep i c k e du p2 4i n d i v i -
dual iPSC-like colonies per each sample based on their
size and morphology at 2 to 3 weeks after viral trans-
duction. Among 24 colonies, three to six colonies were
expandable without spontaneous differentiation under
feeder-free conditions. The reprogramming efficiency
was between two to 10 expandable clones per 10
5 trans-
duced cells (Figure 1b). HPC- and PBMC-derived iPS
clones could be cultured for 5 months after the initial
vector infection (up to passage 50) without showing
signs of replicative crisis. Immunocytochemistry revealed
the expression of SSEA-4, TRA-1-60, OCT4, and
NANOG in the blood-derived iPSC clones (Figure 1b).
Long-term time-lapse imaging demonstrated efficient
iPSC expansion under feeder-free and serum-free condi-
tions. The colonies had a 23.7-hour average cell dou-
bling time (Figure 2a). Frequent mitotic events were
observed in derived iPSC colonies (Figure 2b), and the
duration of mitotic events (from prophase to telophase)
was approximately 60 minutes (Figure 2b and 2c). Simi-
lar results were observed with other two iPSC clones.
Ultrastructural studies of blood-derived iPS cells
High-resolution electron microscope analysis was per-
formed to determine the morphologic differences
between blood-derived iPSCs and verified fibroblast-
derived iPSCs (HCF1) [11]. Blood-derived iPSCs showed
scant cytoplasm and globular-shaped immature mito-
chondria with unorganized cristae, which resembled
those of fibroblast-derived iPS cells (Figure 3a). In con-
trast, non-reprogrammed fibroblasts showed the cyto-
plasm densely packed with membrane-bound organelles
(Figure 3a, upper left panel), including mature mito-
chondria with well-developed cristae (Figure 3a, upper
right panel). In accordance with our cinemicrography
analysis, frequent mitotic events were observed in
blood-derived iPSCs cells (Figure 3b). One pair of cen-
trioles–mother (arrowhead) and daughter (arrow) cen-
trioles–were seen in a dividing cell at anaphase (Figure
3b, lower right panel).
Genome-wide transcriptome analysis of blood-derived iPS
clones
With a microarray representing the genome-wide tran-
scriptome, we determined the global gene-expression
patterns in HPC- and PBMC-derived iPSC clones,
which were then compared with those of fibroblast
(FB)- and epidermal keratinocytes (HK)-derived iPSCs.
Transcriptome data from non-reprogrammed HK cells
were also used as somatic cell controls. The dendro-
gram of unsupervised one-way hierarchic clustering
analysis demonstrated that blood-derived iPSCs clus-
tered closely with other iPSCs from different cell
sources and were distinct from non-reprogrammed HK
cells (Figure 4a). In accordance with this observation,
the global gene-expression patterns of blood-derived
iPSCs were more similar to those in human ES H9
cells and HK-derived iPSCs, rather than to non-repro-
grammed HPCs or PBMCs (Figure 4b). We also noted
that the transcriptome of blood-derived iPSCs was
more closely related to that of HK-derived iPSCs than
of ES H9 cells. This subtle difference may be due to
the fact that the blood- and HK-derived iPSCs were
cultured under the same feeder- and serum-free condi-
tions in our laboratory, whereas the ES H9 transcrip-
tome data were obtained through the GSM database.
Similar to HK- and FB-derived iPSC clones, expression
of pluripotency-associated genes, such as OCT4, SOX2,
NANOG, LIN28,a n dTERT, was markedly upregulated
in HPC- and PBMC-derived iPSC clones (Figure 4c).
When the top 100 differentially expressed genes
between blood-derived iPSC clones and non-repro-
grammed HK cells were analyzed and used to generate
heatmaps, including FB- and HK-derived iPS cells, the
gene-expression patterns of blood-derived iPSCs were
nearly identical to those of iPSCs derived from FB and
HK cells. Among the 200 differentially expressed genes
(100 highest and 100 lowest), notable differences in
gene-expression profiles were found only in XIST (with
three probes, Figure 4d, upper panel), USP9Y, EIF1AY,
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HK-derived iPSC clones (SW3 b and SW3 NI). XIST is
on the × chromosome, and XIST RNA plays a major
role in silencing one of the pair of × chromosomes in
female cells [36], whereas USP9Y, EIF1AY, DDX3Y,
and RPS4Y1 are Y-linked genes. Because HK and HK-
derived iPSC clones were from female patients,
whereas HCF1, HPC-A1, PBMC-S1, and PBMC-S2
were from male patients, the observed variations in X-
and Y-linked genes between blood- and non-blood-
derived iPSC clones are likely due to the difference in
gender of these iPSC clones.
Pluripotency of blood-derived iPS clones verified through
in vitro differentiation
HPC- and PBMC-derived iPSC clones were assayed for
the ability to spontaneously differentiate in vitro into
cells of three embryonic germ layers through embryoid
body (EB) formation. All the iPSC clones assayed
formed EBs. After 7 to 10 days in suspension, EBs were
transferred to a Matrigel-coated plate, and sponta-
neously differentiated cells were expanded under adher-
ent conditions. Immunostaining for lineage-specific
markers showed that blood-derived iPSCs differentiated
into cells of three germ layers, including b-III tubulin-
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Figure 1 Reprogramming of human hematopoietic progenitor and peripheral blood mononuclear cells. (a) HPCs and PBMCs were
cultured in a serum-free medium and transduced with lentiviral vectors expressing four stemness factors at an MOI of 5. Representative phase-
contrast images of HPCs before transduction (left panel) and 7 days after infection (left panel) are shown. Representative HPC-derived (left panel)
and PBMC-derived (right panel) colonies with characteristic morphologies of reprogrammed cells are shown. (b) HPC and PBMC-derived iPSC
clones were further characterized through immunocytochemistry analysis by using a panel of antibodies against pluripotency-associated markers.
All clones stained positive for the markers, including SSEA-4, TRA-1-60, OCT4, and NANOG.
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Figure 2 Efficient expansion of HPC/PBMC-derived iPSC clones under feeder- and serum-free conditions. (a) Long-term time-lapse
images of an iPSC HPC-A1 colony were obtained by using Nikon BioStation IMQ. Time is shown in hours in the upper right corner, and cell
count is shown in the bottom right corner of each panel. (b) Frequent mitotic events were observed during time-lapse imaging. Dividing cells
and daughter cells are indicated by yellow and green arrows. Time is shown in minutes in the upper right corner of each panel. (c) High-
magnification images of a dividing cell at different stages of mitosis (prophase, prometaphase, metaphase, anaphase, and telophase) are
indicated in green arrows. Time is shown in minutes in the upper right corner of each panel.
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CD31-positive mesoderm cells (Figure 5a).
In vivo multilineage differentiation of blood-derived iPSCs
To assess the multilineage differentiation capacity of iPSCs
in vivo, blood-derived iPSCs were transplanted under the
kidney capsule of SCID-beige mice. After transplantation
of 1 million cells, iPSCs formed cystic tumors within 4
weeks (Figure 3b). On gross inspection, iPSC-derived
tumors demonstrated a complex cellular architecture with
prominent vascularization and nonvascularized solid tis-
sues. Histologic analysis revealed iPSC differentiation into
endoderm lineages composed of glandular-like tissue,
mesoderm lineages indicated by muscle-like tissue, and
ectoderm lineages denoted by neural rosette-like struc-
tures (Figure 5b), which verified the multilineage differen-
tiation capability of blood-derived iPSCs.
Generation of insulin-producing cells from iPSCs through
guided differentiation
Next we examined the pancreatic differentiation poten-
tials of blood-derived iPSCs. We used our guided iPSC
differentiation protocol with indolactam V (ILV) and
GLP-1 [11], with minor modifications in medium com-
positions, which are described in Materials and Meth-
ods. Blood-derived iPSC clones were first stimulated
with activin A and Wnt3a to form definitive endoderm
cells. Immunostaining revealed the efficient induction
of definitive endoderm markers SOX17 and FOXA2 in
iPSC-derived cells at day 5 of differentiation (Figure
3c). Derived definitive endoderm cells were further dif-
ferentiated in DMEM/advanced RPMI medium con-
taining FGF10, CYC, and 2% FBS (vol/vol) for 2 days,
and maintained in high-glucose DMEM/advanced
RPMI medium supplemented with FGF10, CYC, RA,
and 1 × B27 for an additional 4 days. Cells were then
c u l t u r e di nt h ep r e s e n c eo fF G F 1 0 ,I L V ,G L P - 1 ,a n d1
× B27 in DMEM/advanced RPMI medium for 4 days.
After this step, derived cells expressed pancreatic
endoderm markers, PDX1 and NKX6.1 (Figure 5d).
Further differentiation of iPSC-derived pancreatic
endoderm cells was performed in DMEM/advanced
RPMI medium supplemented with DAPT, GLP-1, and
1x B27 for 6 days, followed by the final maturation
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Figure 3 Transmission electron microscopic images of blood-derived iPS cells. (a) Representative high-resolution electron micrographs of
primary human fibroblasts (HCF fibroblast), HCF-derived (HCF1 iPS), and HPC-derived (HPC-A1) iPSCs are shown. Mitochondria (MT) and nucleus
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Figure 4 Global gene-expression profiles of blood-derived iPSCs. (a) Dendrogram describing the unsupervised hierarchal clustering of
primary keratinocytes (SW3 HK and SW3 HK), and keratinocyte (HK)-, fibroblast (FB)-, and HPC- and PBMC-derived iPSCs. (b) Genome-wide gene-
expression patterns of HPC- and PBMC-derived iPSC clones were compared with those of HPCs (GSM178554), PBMCs (GSM452255), verified
epidermal keratinocyte-derived iPSCs (SW4#N1, upper panels), or embryonic stem cells (H9 cells, GSM190779). (c) Heatmap demonstrating the
relative expression levels (high, red; low, green) of pluripotency-associated genes in primary keratinocytes (HK) and iPS cells from HK, FB, or
blood cell sources. The changes in gene-expression levels in blood-derived iPSCs, relative to those in HK cells, were calculated by using the
microarray data from three primary HK cells and three blood-derived iPSCs, and shown as fold-increase in iPSCs. Statistically significant changes
are indicated by asterisks (P < 0.05). (d) Heatmap showing the top 100 differentially expressed genes between non-reprogrammed HK and
blood-derived iPSC clones. Highly expressed in non-reprogrammed cells and blood-derived iPSCs are shown in upper and lower panels,
respectively. Genes with notable differences in gene-expression patterns between HK/FB-derived and blood-derived iPSCs are indicated by the
gene symbols on the right.
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Page 8 of 12step in the CMRL-1066 medium containing HGF, IGF-
1, GLP-1, and 1 × B27 for an additional 8 days. Insu-
lin-positive iPSC progeny were sporadically detected
(Figure 5d). High levels of intracellular C-peptide
(230~320 pmol/L), a byproduct of proinsulin proces-
sing during insulin secretion, were also detected in the
final differentiation-stage iPSC progeny with C-peptide
ELISA (data not shown). Our results demonstrate suc-
cessful differentiation of blood-derived iPSCs into insu-
lin-expressing cells in vitro.
The iPSC technology opened the exciting possibility of
generating patient-specific pluripotent stem cells with-
out using an embryonic source, which could pave the
way for personalized pluripotent stem cell therapy
approaches. However, because of the complexity of the
iPSC technology, which typically involves ex vivo gene
delivery and pluripotent stem cell manipulation, multi-
ple issues must be addressed before autologous iPSCs
can contribute to novel individualized cell therapy. One
of the major issues is to develop a GMP-compliant
H
P
C
-
A
1
H
P
C
-
A
3
P
B
M
C
-
S
1
C
-
S
3
Endoderm Mesoderm Ectoderm
iPS  DE  PG PE  ISL 
FGF10
CYC
RA
ILV
GLP-1
DAPT
HGF
IGF
ActA
Wnt
FGF10
CYC
Glandular 
tissue
Neural 
rosettes
Muscular 
tissue
AB
C
D
FOXA2 CD31 ȕIII-Tubulin
P
B
M
C
-
I
2
P
B
M
C
-
I
1
P
B
M
C
PDX1 NKX6.1 INS FOXA2
Day 5 Day 10 Day 24
H
P
C
-
A
1
P
B
M
C
-
S
1
SOX17
Figure 5 Differentiation of blood-derived iPSCs in vitro and in vivo. (a) Blood-derived iPSC clones were spontaneously differentiated
through embryoid body formation, and analyzed via immunocytochemistry for lineage markers for three embryonic germ layers (endoderm
FOXA2, mesoderm CD31, and ectoderm b-III-tubulin). (b) Transplantation of iPSCs into renal capsule of SCID-beige mice resulted in teratoma
formation. Tissue histology of teratomas demonstrated the cells of three germ layers including glandular, muscular, and neural rosette-like
tissues. (c) Schematic diagram describing the stepwise-guided differentiation protocol for iPSC differentiation into islet-like cells. ActA, Activin A;
CYC, cyclopamine; DE, definitive endoderm; FGF10, fibroblast growth factor 10; GLP-1, glucagon-like peptide-1; HGF1, hepatocyte growth factor-1;
IGF, insulin-like growth factor-1; ILV, indolactam V; ISL, islet-like cells; PE, pancreatic endoderm; PG, primitive gut; RA, all-trans retinoic acid; Wnt,
Wnt3a. (d) Through the guided differentiation protocol, HPC- or PBMC-derived iPSC clones were induced to definitive endoderm (day 5),
pancreatic endoderm (day 10), and insulin-producing islet-like cells (day 24). Immunostaining demonstrated the expression of stage-specific
markers in iPSC progeny at day 5 (FOXA2 and SOX17), day 10 (NKX6.1 and PDX1), and day 24 (INS). Scale bars indicate 50 μm.
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Page 9 of 12process for clinical-grade iPSC generation. For this end,
we need simple, robust, and time-effective strategies for
both iPSC derivation and differentiation. Currently, skin
biopsy samples are typically used for iPSC derivation.
However, it takes at least several days (often weeks) to
process and expand skin cells. Here, we demonstrate the
feasibility of iPSC derivation from GMP-grade mobilized
HPCs and unmobilized PBMCs. Although our current
HPC/PBMC iPSC derivation efficiencies (two to five
clones per 10
5 transduced cells) were similar to those of
previous reports [27,29,31,32], generation of iPSCs from
GMP-grade, blood-derived cells represents an important
step toward clinical applications of iPSCs and iPSC pro-
geny cells. The use of HPCs and PBMCs enabled time-
effective iPSC derivation, as the cells did not require
long-term expansion before reprogramming. Moreover,
apart from minor differences in global gene-expression
profiles (Figure 4), blood-derived iPSCs were basically
indistinguishable from iPSCs from other cell sources.
Considering that many institutes/hospitals already have
an FDA-approved GMP facility for autologous HPC pro-
cessing, HPCs and PBMCs would be ideal somatic cell
sources for clinical-grade iPSC derivation.
We and others have reprogrammed blood cells
through genome-integrating viral vectors [37,38]. In our
lentiviral vectors, the transgenes are driven by a retro-
viral promoter. Because retroviral promoter is strongly
suppressed in pluripotent stem cells, we speculate that
the expression of transgene-derived pluripotency factors
is silenced in the blood-derived iPSCs. Nevertheless, the
use of integrating vectors is associated with the risk of
insertional mutagenesis and sustained/reactivated
expression of reprogramming factors, including a proto-
oncogene c-MYC. Indeed, stable c-Myc vector integra-
tion in iPSCs has been linked to increased
tumorigenicity in vivo [39]. Reprogramming blood cells
through non-integrating vectors or introduction of
reprogramming proteins, RNAs, or miRNAs [32,40-45]
would avoid/minimize these safety concerns. We are
currently testing these non-integrating reprogramming
strategies for patient-specific iPSC derivation.
Although islet transplantation has shown some pro-
mising results for type 1 diabetes therapy, the shortage
of matched islet replacement tissues has prevented the
w i d e s p r e a du s eo ft h i st h e r a p yi nt h ec l i n i c .O n ep o s s i -
ble solution to overcome this shortage is to regenerate
transplantable insulin-secreting cells from patient-
derived iPSCs [9]. We previously reported that ILV and
GLP-1 facilitate differentiation of iPSCs into insulin-pro-
ducing cells through a guided differentiation protocol
[11]. Here we demonstrate the feasibility of generating
insulin-producing cells from blood-derived iPSCs. To
our knowledge, this is the fir s tr e p o r ts h o w i n gt h eg e n -
eration of insulin-producing islet-like cells from blood-
d e r i v e di P S C s .I nc o n t r a s tt os k i nb i o p s i e s ,w h i c h
involve an invasive procedure, the use of blood cells
allows minimally invasive tissue procurement for iPSC
derivation. Because diabetes patients often experience
poor wound healing, the minimally invasive iPSC deriva-
tion from blood cell sources would be particularly
advantageous for the generation of clinical-grade iPSCs
from diabetes patients.
Conclusions
Because the use of blood cells allows minimally invasive
tissue procurement under GMP conditions and rapid
cellular reprogramming, mobilized HPCs and unmobi-
lized PBMCs would be ideal somatic cell sources for
clinical-grade iPSC derivation, especially from diabetes
patients complicated by a slow-healing wound.
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